Any current/future new fundraising through debt or equity?

An equity infusion will likely be needed soon to keep Synthix Global Pharma Solutions' balance sheet healthy, as it is currently subscale with weak or negative operating cash flow (Page 7). Regarding fundraising for the CRAMS business, it is "very early days" and more details will likely be provided in the next call (Page 9). There is a plan to push down INR 200 crores of debt to the newly formed CRAMS company, which will improve Solara's net debt-to-EBITDA ratio (Page 4). No immediate or finalized public plans for new major fundraises (debt or equity) were disclosed besides these indications.

Any current/future capex/capital investment/strategic investment?

Solar Active Pharma Sciences Limited plans to invest around INR 200 crores in the first phase to repurpose the Vizag plant, which is currently underutilized at one-third of group capacity, shifting it towards the CRAMS business. No major new capex is required beyond repurposing equipment in this facility. The aim is to grow the CRAMS business to an INR 400-500 crores scale over 3 to 4 years. Incremental capex is planned to increase capacity for key molecules in the generic API business, as current utilization is around 60-65%. The company is in early stages of fundraising (equity or ot

Future growth expectations in sales/revenue/volumes?

Solara expects around 10% revenue growth in FY '26 driven by non-ibuprofen products growing faster than the flat ibuprofen segment. The company plans to pivot from a reset phase (FY '25) to growth with a focus on profitable, sustainable, and scalable expansion. New product launches, cost improvements, market expansion, and incremental capex on key molecules are key growth levers. CRAMS business currently INR100 crores and expected to grow to INR400-500 crores over 3-4 years with INR200 crores initial capex for repurposing existing facilities. Developed markets contribute ~77% to sales,

Future growth expectations in earnings/operating earnings/profits/EPS?

FY '26 is targeted as a growth year following the reset phase in FY '25, focusing on profitable growth. The company expects about 10% top-line (revenue) growth in FY '26. EBITDA growth guidance is around 15% to 20% for FY '26. Q1 FY '26 showed healthy gross margin (~54%) and EBITDA margin (~18%) with INR57 crores EBITDA. PAT in Q1 FY '26 was INR105 million, the highest in 12+ quarters, with EPS at INR 2.5 per share. The company aims to maintain gross margins in the 53%-55% range sustainably. Cost improvement and operational efficiency will support margin expansion. Debt reduction and network o

Current/ Expected Orderbook/ Pending Orders?

The transcript does not provide specific details about the current or expected order book or pending orders for Solara Active Pharma Sciences Limited. However, the management highlighted plans to grow the CRAMS business by repurposing an underutilized plant in Vizag with a capex of around INR 200 crores in the first phase to reach a INR 400-500 crores business over 3-4 years. The company is focusing on new products, cost improvements, new markets, and capacity enhancements to drive growth. They have also indicated onboarding new CRAMS customers in the second half of the current year. Overall,

Solara ActiveQ1 FY26Pharmaceuticals & Biotechnology

Solara Active Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹645.65P/E: 66.2Market Cap: ₹3.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Solara expects around 10% revenue growth in FY '26 driven by non-ibuprofen products growing faster than the flat ibuprofen segment.
The company plans to pivot from a reset phase (FY '25) to growth with a focus on profitable, sustainable, and scalable expansion.
New product launches, cost improvements, market expansion, and incremental capex on key molecules are key growth levers.
CRAMS business currently INR100 crores and expected to grow to INR400-500 crores over 3-4 years with INR200 crores initial capex for repurposing existing facilities.
Developed markets contribute ~77% to sales, with a focus on high-margin business with marquee customers.
Capacity utilization is ~60-65%, with incremental capacity being added selectively to support growth.
The company is cautious about generic ibuprofen due to intense competition and is focusing on derivatives and complex derivatives for healthier margins.

Margin guidance

Category 3

FY '26 is targeted as a growth year following the reset phase in FY '25, focusing on profitable growth.
The company expects about 10% top-line (revenue) growth in FY '26.
EBITDA growth guidance is around 15% to 20% for FY '26.
Q1 FY '26 showed healthy gross margin (~54%) and EBITDA margin (~18%) with INR57 crores EBITDA.
PAT in Q1 FY '26 was INR105 million, the highest in 12+ quarters, with EPS at INR 2.5 per share.
The company aims to maintain gross margins in the 53%-55% range sustainably.
Cost improvement and operational efficiency will support margin expansion.
Debt reduction and network optimization will contribute to improving overall financial health.
CRAMS business growth will be gradual over 3-4 years, requiring some capex and investments, impacting earnings progressively.

See what Solara Active management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

An equity infusion will likely be needed soon to keep Synthix Global Pharma Solutions' balance sheet healthy, as it is currently subscale with weak or negative operating cash flow (Page 7).
Regarding fundraising for the CRAMS business, it is "very early days" and more details will likely be provided in the next call (Page 9).
There is a plan to push down INR 200 crores of debt to the newly formed CRAMS company, which will improve Solara's net debt-to-EBITDA ratio (Page 4).
No immediate or finalized public plans for new major fundraises (debt or equity) were disclosed besides these indications.

Order book

The transcript does not provide specific details about the current or expected order book or pending orders for Solara Active Pharma Sciences Limited.
However, the management highlighted plans to grow the CRAMS business by repurposing an underutilized plant in Vizag with a capex of around INR 200 crores in the first phase to reach a INR 400-500 crores business over 3-4 years.
The company is focusing on new products, cost improvements, new markets, and capacity enhancements to drive growth.
They have also indicated onboarding new CRAMS customers in the second half of the current year.
Overall, Solara is in a reset phase with emphasis on operational efficiency, margin expansion, and gradual growth rather than aggressive expansion, implying a cautious but steady build-up of order pipeline.

See what Solara Active management said on order book — free account, 30 seconds.

Capex plans

Yes

Solar Active Pharma Sciences Limited plans to invest around INR 200 crores in the first phase to repurpose the Vizag plant, which is currently underutilized at one-third of group capacity, shifting it towards the CRAMS business.
No major new capex is required beyond repurposing equipment in this facility.
The aim is to grow the CRAMS business to an INR 400-500 crores scale over 3 to 4 years.
Incremental capex is planned to increase capacity for key molecules in the generic API business, as current utilization is around 60-65%.
The company is in early stages of fundraising (equity or otherwise) for the CRAMS business, with more clarity expected in upcoming quarters.
Additional capex or equity infusion may be required for subscale entities like Synthix Global Pharma Solutions to support growth and keep the balance sheet healthy.

Track Solara Active — get its next earnings analysis in your feed

How does Solara Active rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisSolara Active

Rev 3Mar 3

See where Solara Active sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Solara Active rank in Pharmaceuticals & Biotechnology?

Compare Solara Active against every Pharmaceuticals & Biotechnology company (Q1 FY26) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Solara Active's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Himalaya Nutravedics (Q2 FY27)
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Solara Active Q1 FY26 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Solara Active rank in Pharmaceuticals & Biotechnology?

Continue your research

What Solara Active's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season